

# Ensuring Medication for Opioid Use Disorder (MOUD) Treatment through the Care Continuum Webinar Series



## Seamlessly Transitioning Patients on MOUD to Nursing Homes (NHs) Part 2

Friday, January 12, 2024

In partnership with all Quality Innovation Network-Quality Improvement Organizations (QIN-QIOs)



# QIN-QIO Partnership to Address the Opioid Epidemic

This series is a collaboration of all QIN-QIOs. National experts across the healthcare continuum provide robust educational content to address the opioid epidemic.



# Learning Objectives

- Discuss the discharge planning process to safely transition patients on MOUD to a NH and/or in the community.
- Review the steps of an effective medication reconciliation process.
- Learn more about effective strategies and interventions to implement a strong partnership with post-acute care facilities and primary care physicians.



# Hosts



**Jennifer Massey, PharmD**

Pharmacist– ADE Technical Advisor

Alliant Health Solutions



**Rob Accetta, RPh, BCGP, FASCP**

Senior Pharmacist

I PRO

# Guest Panelists



**Melissa Cheng, MD, MOH, MHS, FACOEM**

Medical director

Comagine



**Jonathon Pouliot, MS, PharmD, BCPS**

Associate professor and consultant

Qsource and Lipscomb University



**RoseAnna Milanovic, MA, MS**

Senior quality improvement facilitator

Telligen

Could you tell us more about  
your role related to opioid safety?



# Key Takeaways From the Part 1 Session: November 2023

## Speakers

- Aimee Moulin, MD, MAS
- Jennifer Miranda, PharmD, BCACP, CPP

## Key Points

- Maintain contact with opioid treatment program for enrolled patients.
- Dispense 3-day supply on discharge.
- Facilitate intake at opioid treatment program on discharge or during hospitalization via telehealth.
- Importance of communication and coordination to develop workflows with post care providers.



# Key Takeaways From the Part 1 Session: November 2023 (cont.)

## Key Points

- Importance of medication reconciliation to reduce adverse drug events.
- Perform medication reconciliation within three to seven days post-discharge decreased hospital readmissions and contribute to cost savings.
- Medication reconciliation for a person with OUD should be prioritized as inappropriate medication regimens can lead to withdrawal or toxicity.
- The D's of monitoring: Drug-drug interactions, drug-disease interactions, duplications.
- Keep naloxone handy and provide education.





## Polling Question:

What are the most effective strategies to safely transition patients on MOUD to NHs?

- Intake at OTP upon discharge or during hospitalization via telehealth
- Maintain contact with OTP for enrolled patients
- Dispense 3-day supply of MOUD on discharge
- Dispense 14-day supply of MOUD on discharge
- Perform medication reconciliation shortly after discharge/Prioritize medication reconciliation for a person on MOUD
- Provide a verbal and written handoff to NH personnel explaining the rational, dosing, and treatment plan for the patient's MOUD
- Provide education about stigma, naloxone use in the NH setting
- Other: *Please write your comments in the chat box*



What are the most effective strategies to safely transition patients on MOUD to NHs?



Could you share one success story?



Could you share one resource and/or tool?



# Medications for Substance Use Disorder SAMHSA website



The screenshot shows the SAMHSA website's navigation and content. At the top, there is a header with the SAMHSA logo, a search bar, and a navigation menu. The main content area features a sidebar with a list of links related to substance use disorders, a large banner image of a doctor and patient, and a featured article about methadone take-home flexibilities.

An official website of the United States government [Here's how you know](#) In Crisis? Call or Text 988 >>

**SAMHSA**  
Substance Abuse and Mental Health  
Services Administration

Home | Site Map | Contact Us

Search SAMHSA.gov

Find Help | Practitioner Training | Public Messages | Grants | Data | Programs | Newsroom | About Us | Publications

[Home](#) » [Programs](#) » Medications for Substance Use Disorders f x e

**Medications for Substance Use Disorders**

- Medications, Counseling, and Related Conditions
- Find Substance Use Disorder Treatment
- Waiver Elimination (MAT Act)
- Training Requirements (MATE Act) Resources
- Pharmacist Verification of Buprenorphine Providers
- Become an Accredited and Certified Opioid Treatment Program (OTP)
- OTP Resources and Information
- State Opioid Treatment Authority (SOTA)
- Statutes, Regulations, and Guidelines
- Training Materials and Resources
- About SAMHSA's Division of Pharmacologic Therapies (DPT)

**Medications for Substance Use Disorders**


**i** [2021 Methadone Take-Home Flexibilities Extension Guidance \(Updated July 2023\)](#)  
[Removal of DATA Waiver \(X-Waiver\) Requirement](#)

Learn how medications can be used to treat substance use disorders, sustain recovery and prevent overdose.

The use of medications, in combination with [counseling and behavioral therapies](#), to provide a “whole-patient” approach to the treatment of substance use disorders. [Medications used](#) are approved by the [Food and Drug Administration \(FDA\)](#) and are clinically driven and tailored to meet each patient’s needs.

SAMHSA=Substance Abuse and Mental Health Services Administration  
<https://www.samhsa.gov/medications-substance-use-disorders>

# AHRQ: Medication at Transitions and Clinical Handoffs (MATCH) Toolkit for Medication Reconciliation




- This toolkit will help you evaluate the effectiveness of your existing medication reconciliation process
- Identify and respond to any gaps in your current process
- Promotes a successful approach to medication management and reconciliation
- Emphasizes standardization of documentation

# Center of Excellence for Behavioral Health in NHs

**The Center of Excellence focuses on increasing the knowledge, competency, and confidence of NH staff members to care for residents with behavioral health conditions.**

- Provides mental health and substance use trainings, customized technical assistance and resources at no cost
- Services are available to all Centers for Medicare & Medicaid Services (CMS) certified NHs throughout the United States
- Established by SAMHSA in collaboration with CMS



**For assistance, submit a request at [nursinghomebehavioralhealth.org](https://nursinghomebehavioralhealth.org)**

## **Contact**

**National Call Center: 1.844.314.1433**

## **Email**

**[coeinfo@allianthealth.org](mailto:coeinfo@allianthealth.org)**



# Questions?

**Melissa Cheng, MD, MOH, MHS, FACOEM**

[Mcheng@comagine.org](mailto:Mcheng@comagine.org)

**Jonathon Pouliot, MS, PharmD, BCPS**

[Jpouliot@qsource.org](mailto:Jpouliot@qsource.org)

**RoseAnna Milanovic, MA, MS**

[Ramilanovic@telligen.com](mailto:Ramilanovic@telligen.com)

**Jennifer Massey, PharmD**

[Jennifer.Massey@allianthealth.org](mailto:Jennifer.Massey@allianthealth.org)

**Rob Accetta, RPh, BCGP, FASCP**

[Raccetta@ipro.org](mailto:Raccetta@ipro.org)





# Your State-Specific QIO Point of Contact



Login: SAFE | Employees Select Language A A A

[Home](#) [About](#) [Careers](#) [Contact](#)

You are here: [Home](#) ▶ [Medicare Quality Improvement \(QIO\)](#) ▶ [Opioid Stewardship Program Events](#) ▶ [QIO Collaborative Opioid Series](#)

## QIO Collaborative Opioid Series



### Ensuring Medication for Opioid Use Disorder (MOUD) Treatment through the Care Continuum Webinar Series

*More than 1 million Medicare beneficiaries had a diagnosis of opioid use disorder (OUD) in 2020.<sup>1</sup> However, fewer than 1 in 5 Medicare beneficiaries with an opioid use disorder diagnosis received medication to treat this condition. In addition, the number of patients who stay in treatment after hospital discharge decrease drastically during the transition of care.<sup>2</sup>*

This webinar series is a collaboration of all of the Quality Improvement Organizations and will provide strategies, interventions, and targeted solutions to ensure access to MOUD treatment and facilitate the continuity of care through the continuum.

Please join us to hear from national experts during this monthly webinar series occurring on Friday of the month from September 2023 through June 2024 at 12 noon ET, 11 a.m. CT, 10 a.m. MT, 9 a.m. PT.

**Register for this no-cost series at: [bit.ly/MOUDthroughCareContinuumSeries](https://bit.ly/MOUDthroughCareContinuumSeries)**

A general certificate of attendance will be provided for continuing education/contact hours. Attendees are responsible for determining if this program meets the criteria for licensure or recertification for their discipline.

- Session 1: Role of the Emergency Department (ED) Physician in the Treatment of Patients with OUD
- Session 2: Role of the Pharmacist in the Treatment of Patients with OUD
- Session 3: Seamlessly Transitioning Patients on MOUD to Nursing Homes | Formal Presentation
- Session 4: Seamlessly Transitioning Patients on MOUD to Nursing Homes | Panel Discussion

- Session 9: Management of Patients on MOUD: Key Takeaways and Series Wrap Up

### Upcoming Events

January 12, 2024	QIO Collaborative Opioid Series
February 09, 2024	QIO Collaborative Opioid Series
March 08, 2024	QIO Collaborative Opioid Series

[See All Events](#)

<https://www.hsag.com/qiocollabopioidseries>

Session 1—September 15, 2023



# What's Next


Join us for the next session on February 9, 2024: **Management of Patients on MOUD During the NH Stay—Part 1**



[bit.ly/MOUDthroughCareContinuumSeries](https://bit.ly/MOUDthroughCareContinuumSeries)

Recordings, slides, and resource links are posted for on-demand access 72 hours after every session.

<https://www.hsag.com/qiocollabopioidseries>

QIO Collaborative Opioid Series 

Ensuring Medication for Opioid Use Disorder (MOUD) Treatment through the Care Continuum Webinar Series

*More than 1 million of Medicare beneficiaries had a diagnosis of opioid use disorder in 2020.<sup>1</sup>*

*However, fewer than 1 in 5 Medicare beneficiaries with an opioid use disorder diagnosis received medication to treat this condition. In addition, the number of patients who stay in treatment after hospital discharge decrease drastically during the transition of care.<sup>2</sup>*

This series of webinars is a collaboration of all of the Quality Improvement Organizations and will provide strategies, interventions, and targeted solutions to ensure access to treatment and facilitate the continuity of care through the continuum.

Please join us to hear from leading national experts monthly on Fridays from September 2023 through June 2024 at 12 noon ET, 11 a.m. MT and CST, 9 a.m. PT.

**Register for this no-cost series at:**  
<https://bit.ly/MOUDthroughCareContinuumSeries>

A general certificate of attendance will be provided for continuing education/contact hours. Attendees are responsible for determining if this program meets the criteria for licensure or recertification for their discipline.

- Session 1—September 15, 2023
- Session 2—October 13, 2023
- Sessions 3 (Part 1) and 4 (Part 4)—November 17, 2023, and January 12, 2024
- Sessions 5 and 6—February 9, 2024, and March 8, 2024
- Sessions 7 and 8—April 12, 2024, and May 10, 2024
- Session 9—June 7, 2024

# Certificate of Attendance

## Continuing Education (CE) Credits and Contact Hours for Health Professionals

- This series may meet CE requirements for your discipline. You may use this certificate as proof of attendance. It is your responsibility to determine if the series fulfills that requirement.
- The link to request a certificate of attendance is below and will be included in the follow-up email sent directly to you by Webex.
  - New User Registration Link: <https://lmc.hshapps.com/register/default.aspx?ID=e88fe8ec-3ebd-47be-935e-06cc141ff36c>
  - Existing User Link: <https://lmc.hshapps.com/test/adduser.aspx?ID=e88fe8ec-3ebd-47be-935e-06cc141ff36c>





# Thank You

This material was prepared by Health Services Advisory Group, a Quality Innovation Network-Quality Improvement Organization under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication number: QN-12SOW-XC-01112024-05.